Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H44O3 |
| Molecular Weight | 416.6365 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]16CC[C@H](C)CO6
InChI
InChIKey=GMBQZIIUCVWOCD-WWASVFFGSA-N
InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17-,18+,19-,20+,21-,22-,23-,24-,25-,26-,27+/m0/s1
| Molecular Formula | C27H44O3 |
| Molecular Weight | 416.6365 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PYM50018 (also known as Myogane or SARSAGENIN) has demonstrated neuroprotective effects in several preclinical models. It was observed that PYM50018 protects against neuronal damage, increases neurite outgrowth, reverses oxidative damage and reversed neuronal apoptosis. PYM50018 is in phase I clinical study for the treatment of amyotrophic lateral sclerosis (ALS).
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:52:43 GMT 2025
by
admin
on
Wed Apr 02 09:52:43 GMT 2025
|
| Record UNII |
CFS802C28F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C823
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/08/543
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
||
|
FDA ORPHAN DRUG |
185704
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CFS802C28F
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
9639
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
1615
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
m9787
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID00903921
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
C152305
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
204-776-3
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
15578
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
126-19-2
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
92095
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
100000177287
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY | |||
|
SARSASAPOGENIN
Created by
admin on Wed Apr 02 09:52:43 GMT 2025 , Edited by admin on Wed Apr 02 09:52:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|